India Pharma Outlook Team | Monday, 08 June 2026
India is preparing a major policy initiative aimed at boosting domestic pharmaceutical innovation, with the government working on a new scheme focused on the bulk drug research ecosystem.
The proposed initiative is expected to strengthen India's capabilities in bulk drug development, encourage research and development (R&D), and reduce the country's dependence on imports for critical pharmaceutical ingredients.
The bulk drug research ecosystem has become a key focus area as the government seeks to build a more resilient and self-reliant pharmaceutical sector capable of supporting long-term growth and innovation.
The announcement was made by Pharmaceuticals Secretary Manoj Joshi, who said that the Department of Pharmaceuticals is developing a comprehensive scheme to support research and development activities in the bulk drugs segment. The move comes as India continues to position itself as a global pharmaceutical manufacturing hub while simultaneously addressing supply chain vulnerabilities exposed in recent years.
According to the Pharmaceuticals Secretary, the upcoming scheme will go beyond traditional production-linked incentives and place greater emphasis on research, innovation, and technology development. The government is exploring various support mechanisms, including grants, infrastructure assistance, and funding for R&D activities.
The initiative is expected to create a favorable environment for pharmaceutical companies, research institutions, and academia to collaborate on developing critical bulk drugs and active pharmaceutical ingredients (APIs). Officials believe that strengthening domestic R&D capabilities will help India reduce its reliance on imported raw materials and improve the competitiveness of its pharmaceutical industry.
The proposed framework is also likely to offer greater flexibility to participating companies, including extended timelines for project implementation and support for infrastructure creation.
Also Read: How Digital Maturity is Powering Pharma's GMP Evolution
India is one of the world's largest producers of generic medicines, but the country continues to rely significantly on imports for several key active pharmaceutical ingredients. This dependence has remained a concern for policymakers, particularly after global supply chain disruptions highlighted the need for stronger domestic manufacturing capabilities.
The planned scheme aims to address these challenges by encouraging the discovery, development, and commercialization of bulk drugs within the country. By supporting indigenous research and innovation, the government hopes to create a sustainable ecosystem capable of meeting domestic demand while also enhancing export opportunities.
Industry experts believe that a stronger bulk drug ecosystem could help improve supply chain security, reduce import bills, and increase India's strategic independence in the pharmaceutical sector.
The government's latest initiative reflects a broader shift in policy from simply increasing production capacity to fostering innovation-led growth. While existing Production Linked Incentive (PLI) schemes have helped boost manufacturing investments, the new proposal seeks to create long-term value through scientific research and technological advancement.
Officials are evaluating multiple options that could support companies engaged in advanced research, process development, and commercialization of critical pharmaceutical ingredients. The scheme may also encourage partnerships between industry stakeholders, academic institutions, and research organizations to accelerate innovation.
Such collaborations are expected to play an important role in developing next-generation pharmaceutical technologies and strengthening India's position in the global healthcare supply chain.
The proposed bulk drug R&D scheme is expected to complement several ongoing government initiatives aimed at strengthening the pharmaceutical sector. India has already launched bulk drug parks and PLI programs to encourage domestic production of key ingredients and reduce import dependence.
The government has also introduced broader measures to support pharmaceutical innovation and biopharmaceutical development. These efforts are designed to create a robust ecosystem that supports research, manufacturing, and commercialization across multiple segments of the healthcare industry.
By integrating R&D support with manufacturing incentives, policymakers aim to create a comprehensive framework that promotes sustainable growth across the pharmaceutical value chain.
If implemented effectively, the proposed scheme could mark a significant milestone for India's pharmaceutical industry. Increased investment in research and development could lead to the creation of new technologies, improved manufacturing processes, and greater self-sufficiency in critical drug ingredients.
The initiative may also attract fresh investments from domestic and international pharmaceutical companies looking to expand their research capabilities in India. Additionally, stronger innovation infrastructure could help Indian firms move beyond generic drug manufacturing and participate more actively in high-value pharmaceutical development.
As details of the scheme continue to emerge, industry stakeholders will be closely monitoring how the government structures incentives, funding mechanisms, and implementation timelines. The success of the initiative could play a crucial role in shaping the future of India's pharmaceutical sector and strengthening its position as a global healthcare powerhouse.
.jpg)
